Faster global financial news!
Replimune wins FDA approval for its skin cancer drug, but shares tumble
Replimune has received FDA approval for its skin cancer drug, marking a successful third attempt to gain clearance. Despite the approval, the company's shares are tumbling.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
ZEC (Zcash) is up 6.26% over the past 4 hours, currently trading at $1,330.13.
-
2
The Shanghai Composite Index fell 1.06% from its previous close, currently trading at 3,650.85.
-
3
The Nikkei 225 Index fell 5.76% from its previous close, currently trading at 57,557.09.
-
4
Taiwan Stock Exchange Weighted Index fell 6.11% from its previous close, currently trading at 39,032.95.
-
5
Brent crude was up 3.52% from its previous close, currently trading at $98.354.
-
6
AUD/USD fell 0.89% from its previous close, currently trading at 0.6946.
-
7
South Korea's KOSPI index fell 5.48% from its previous close, currently standing at 5,088.79.
-
8
What is MTH (Monetha)? Project Positioning and Token Supply Analysis
-
9
Where to Buy MANA? A Comprehensive Guide to Decentraland Tokens and Mainstream Trading Channels
-
10
Trump's policies and institutional participation drove Ethereum's sharp rally in August 2026, with its market cap reaching approximately $294.8 billion in November
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
